The Oxford AstraZeneca combine COVID-19 vaccine is not yet ready but may be ready for use by the end of 2020.
The Oxford AstraZeneca combine COVID-19 vaccine is not yet ready but may be ready for use by the end of 2020.On April 30, 2020, AstraZeneca and the University of Oxford had announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19. The early-stage clinical trials showed that the vaccine produced both neutralizing antibodies and T-cells, which can disable the coronavirus. Prof Andrew Pollard, from the Oxford research group, said that the results were promising, but it was too early to say that the vaccine will work. Large trials are underway to know if it can offer protection, and experts are hoping it could be in use by the end of 2020.
This potential vaccine, however, needs many more extensive trials to hit the market and a comprehensive is necessary before determining its effectiveness on a human patient.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.
Copied!